Achillion Pharmaceuticals Inc
ACHN:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 7.77 | 0.21 2.78% | 0.00% | 823,358 | 675.6K |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Achillion Pharmaceuticals Inc
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV.
Achillion to Present at Three Upcoming Investor Conferences
View more recent headlines
Achillion to Present at Three Upcoming Investor Conferences
NEW HAVEN, Conn., May 9, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at three upcoming investor conferences:
Company Background
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 7.60 | Previous Close 7.56 |
Day High 7.815 | Day Low 7.56 |
52wk High/Date 11.36 / 10/16/2012 | 52wk Low/Date 5.42 / 8/10/2012 |
% off 52wk High -31.60% | % off 52wk Low 43.36% |
Beta (5 Yr) 0.7 | Market Capitalization 750.2M |
Shares Outstanding 96.6M | Volatility Avg 55.51 |
EPS(TTM) -0.64 | P/E Ratio Not Meaningful |
Dividend Announcement -- | Dividend Yield 0.00% |
Ex-Date -- | Date of Record -- |
Payable 0.00 - -- | Payable Date -- |
Last Trade as of 5/17/2013 4:00 PM ET | |
ACHN Achillion Pharmaceuticals Inc vs. Peers
| Peers | |
|---|---|
ACHN Achillion Pharmaceuticals Inc | -3.00% |
Pfizer Inc. | 15.47% |
Johnson & Johnson | 25.66% |
Merck & Co., Inc. | 12.34% |
ACHN Achillion Pharmaceuticals Inc | 0.00% |
Pfizer Inc. | 3.31% |
Johnson & Johnson | 3.00% |
Merck & Co., Inc. | 3.74% |
ACHN Achillion Pharmaceuticals Inc | 2.78% |
Pfizer Inc. | -0.99% |
Johnson & Johnson | 0.73% |
Merck & Co., Inc. | -0.82% |